Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Zoetis Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Price to Earnings (P/E) since 2012
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Zoetis Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The financial data indicates consistent profitability and efficiency trends over the analyzed periods. Margins have shown stability with subtle improvements in key profitability indicators, while returns on equity and assets reflect the company's effective utilization of resources.
- Gross Profit Margin
- The gross profit margin remained relatively stable throughout the observed timeframe, fluctuating narrowly around the high 60% to low 70% range. Starting at 69.51% in March 2020, it experienced minor increases, peaking at approximately 70.56% in March 2022, before stabilizing again near 70.05% in March 2024. This stability suggests steady control over the direct costs related to production or service delivery.
- Operating Profit Margin
- Operating margin illustrated a positive upward trajectory overall, advancing from 32.72% in March 2020 to roughly 35.56% by March 2024. Despite small fluctuations, the margin consistently held above 33%, reflecting improving operational efficiency or effective management of operating expenses over time.
- Net Profit Margin
- The net profit margin exhibited a gradual enhancement, rising from 25.41% in March 2020 to around 27.38% in March 2024. This increase indicates strengthening profitability after all expenses, including taxes and interest, suggesting overall financial health and favorable bottom-line performance.
- Return on Equity (ROE)
- ROE experienced a noticeable decline in the initial periods, dropping from 58.52% in March 2020 to a low point of approximately 42.36% in September 2021. Subsequently, it recovered modestly, stabilizing around the mid-40% range and reaching 47.27% by March 2024. This pattern indicates transient challenges in generating profit from shareholders' equity but eventual recovery and consistent performance in generating returns.
- Return on Assets (ROA)
- ROA showed a clear upward trend, increasing from 13.97% in March 2020 to 16.66% in March 2024. This steady growth suggests improved efficiency in utilizing assets to generate net income, contributing positively to overall asset management effectiveness.
Return on Sales
Return on Investment
Gross Profit Margin
Zoetis Inc., gross profit margin calculation (quarterly data)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2024 Calculation
Gross profit margin = 100
× (Gross profitQ1 2024
+ Gross profitQ4 2023
+ Gross profitQ3 2023
+ Gross profitQ2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue exhibited a consistent upward trajectory from March 2020 through March 2024, increasing from approximately 1.53 billion USD to about 2.19 billion USD. Notable increments occurred in mid-2021 and from mid-2022 onwards, indicating robust top-line growth across the observed periods.
- Gross Profit Analysis
- Gross profit mirrored the revenue trend, generally rising from 1.08 billion USD in March 2020 to around 1.55 billion USD by March 2024. Although some quarterly fluctuations appeared, particularly in late 2022 and early 2023, gross profit maintained an overall positive trend, reflecting effective cost management or pricing strategies aligned with revenue growth.
- Gross Profit Margin Stability
- The gross profit margin percentage demonstrated remarkable stability throughout the entire period, fluctuating narrowly between approximately 69.2% and 70.5%. This consistency suggests steady production efficiency and cost control despite increasing revenue levels.
- Quarterly Variations and Seasonality
- Quarterly data reveals minor variances typical for operational and market conditions, such as gross profit dips in late 2022 juxtaposed with a subsequent rebound. However, no significant seasonal patterns are immediately evident, as margins and profits maintained relative steadiness.
- Overall Financial Health Implications
- The steady increase in revenue combined with stable and high gross profit margins indicates healthy financial performance. The company appears capable of scaling operations while maintaining profitability, suggesting effective management of cost of goods sold relative to revenue growth.
Operating Profit Margin
Zoetis Inc., operating profit margin calculation (quarterly data)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Operating income | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2024 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2024
+ Operating incomeQ4 2023
+ Operating incomeQ3 2023
+ Operating incomeQ2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue demonstrated a general upward trajectory from the first quarter of 2020 through the first quarter of 2024. Starting at $1,534 million in March 2020, it increased steadily with occasional minor fluctuations, reaching a peak of $2,213 million in December 2023, before slightly decreasing to $2,190 million in March 2024. This growth indicates a strong expansion over the five-year period.
- Operating Income Patterns
- Operating income showed cyclic fluctuations but maintained a positive growth trend overall. From $530 million in March 2020, it increased to highs above $700 million in several quarters, notably peaking at $826 million in June 2023. Despite some downturns, such as the dip to $510 million in December 2020 and $688 million in December 2022, the operating income remained comparatively strong in the range of $700 million in early 2024.
- Operating Profit Margin Analysis
- The operating profit margin consistently hovered in the mid-30% range across all periods, reflecting stable profitability relative to revenue. Beginning at approximately 32.7% in early 2020, the margin improved steadily, peaking around 36.1% in December 2022. Subsequent quarters showed slight variations but maintained a margin near or above 35%, indicating effective cost control and operating efficiency throughout the period.
- Overall Financial Health and Efficiency
- The data reveals an improving financial performance characterized by both rising revenues and strong profit margins. Operating income and profit margins indicate that the company managed to enhance operational efficiency despite market fluctuations. The ability to sustain robust margins above 35% alongside increasing revenue points to a resilient business model with effective control over operating expenses relative to income.
- Short-term Variability
- While longer-term trends are positive, certain quarters experienced declines or slower growth, such as operating income in late 2020 and late 2022. These could reflect seasonal factors, market conditions, or specific operational challenges. However, recovery in subsequent quarters demonstrates overall resilience and adaptability in financial performance.
Net Profit Margin
Zoetis Inc., net profit margin calculation (quarterly data)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2024 Calculation
Net profit margin = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue demonstrates a general upward trend over the observed periods. Starting from $1,534 million in the first quarter of 2020, it steadily increased, reaching $2,190 million by the first quarter of 2024. Despite minor fluctuations, revenue showed consistent growth with occasional slight dips in certain quarters, such as between December 2022 and March 2023, before continuing its upward trajectory.
- Net Income Patterns
- Net income attributable to the company exhibited variability but generally mirrored the revenue growth pattern. Initial figures in early 2020 hovered around the $400 million mark, with some fluctuations throughout the quarters. There were noticeable peaks, for instance, $671 million in June 2023, indicating strong profitability, followed by a decline and stabilization near $599 million by March 2024. These variations suggest sensitivity to market conditions or operational factors affecting profitability.
- Net Profit Margin Observations
- Net profit margin percentages stayed relatively stable with a slight increasing trend. Starting at approximately 25.4% in early 2020, margins fluctuated mildly but generally improved over time, reaching around 27.4% by early 2024. This indicates effective cost management or pricing strategies that maintained or enhanced profitability relative to revenue.
- Combined Insights
- The simultaneous increase in revenue and improvement in net profit margin reflect positively on operational efficiency and market positioning. While net income shows some volatility, its overall increase aligns with the growing revenue base and stable margin trends. The data suggests the company is successfully expanding its top-line performance while preserving or improving profitability ratios.
Return on Equity (ROE)
Zoetis Inc., ROE calculation (quarterly data)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | |||||||||||||||||||||||
| Total Zoetis Inc. equity | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2024 Calculation
ROE = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ Total Zoetis Inc. equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income Attributable to Zoetis Inc.
- The net income shows noticeable fluctuations across the observed periods. Starting at 423 million US dollars in March 2020, it experienced a decline in June and December 2020, reaching its lowest point at 359 million in December 2020. From early 2021 onward, net income generally trended upward, peaking at 671 million in June 2023. However, there were some periods of decline, notably between December 2023 and March 2024, where net income fell from 525 million to 599 million. Overall, the data suggests a recovery and growth phase after the mid-2020 dip, with some volatility in the most recent quarters.
- Total Zoetis Inc. Equity
- Total equity steadily increased over time, starting at 2,753 million US dollars in March 2020 and rising to over 5,000 million US dollars by the end of the period in March 2024. The growth was relatively consistent, with a minor decrease in the fourth quarter of 2022, after which equity continued to rise again. This trend indicates strengthening equity base and potentially retained earnings or capital contributions supporting the company's financial structure.
- Return on Equity (ROE)
- ROE demonstrates an overall high level of profitability relative to equity throughout the period, consistently remaining above 40%. Beginning at 58.52% in March 2020, it declined notably during 2020, reaching approximately 43.46% by December 2020. Post this decline, ROE stabilized mostly within the 44% to 48% range, with slight fluctuations each quarter. The consistency in ROE from 2021 through early 2024 reflects effective utilization of equity to generate income despite periodic variations in net income and equity values.
- Summary and Insights
- The quarter-to-quarter analysis reveals that despite some volatility in net income, the company maintained a solid growth trajectory in equity, supporting sustained returns to shareholders as seen in stable ROE levels. The dip in net income during 2020 aligns with broader economic challenges, but the recovery and subsequent growth suggest operational resilience. The stable and relatively high ROE indicates efficient management of equity capital during fluctuating profit conditions. The slight recent decreases in net income do not appear to have significantly impacted overall profitability ratios or equity strength.
Return on Assets (ROA)
Zoetis Inc., ROA calculation (quarterly data)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2024 Calculation
ROA = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income Attributable to Zoetis Inc.
-
Net income demonstrates a generally positive trend over the observed periods, with some fluctuations quarter to quarter. Starting at 423 million USD in the first quarter of 2020, the figure experienced a dip in the second quarter of 2020 but then showed recoveries and growth phases. Noticeable peaks include 671 million USD in the second quarter of 2023, which represents the highest recorded net income in the timeframe. The most recent data point for the first quarter of 2024 indicates a solid net income of 599 million USD, showing stability after the prior peak.
- Total Assets
-
Total assets experienced moderate growth through the period, beginning at 11.5 billion USD in the first quarter of 2020 and steadily increasing to approximately 14.3 billion USD by the first quarter of 2024. Despite minor quarter-to-quarter fluctuations, the overall asset base expanded, demonstrating capital accumulation or acquisition over time. An outlier is observed in the fourth quarter of 2022 when assets reached a high of about 14.9 billion USD before slightly retracting and stabilizing thereafter.
- Return on Assets (ROA)
-
The ROA metric shows a consistent upward trend throughout the periods under review, starting at 13.97% in the first quarter of 2020 and rising steadily to 16.66% by the first quarter of 2024. This increase indicates improved efficiency in utilizing the asset base to generate net income. Despite some minor quarterly variability, the general momentum is positive, with ROA reaching its peak in the final quarter of 2023 and maintaining the higher level into early 2024.
- Summary Insights
-
The data suggests that the company has managed to grow both its asset base and profitability simultaneously over the observed period. The rising ROA highlights an improvement in operational efficiency and profitability relative to the asset size, suggesting effective management and possibly favorable market conditions. The fluctuations in net income reflect typical quarter-to-quarter variability, but the upward trend and recovery after dips denote resilience in earnings performance.